Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
copper-64-labeled MAB 1A3
- Development stage
- Preclinical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Copper-64-labeled MAB 1A3 is a radiolabeled murine monoclonal antibody designed for radioimmunotherapy and imaging of human colon cancer. The parent antibody, MAb 1A3, specifically binds to a lipid antigen that is enriched in human colon carcinoma cells. When conjugated with the chelator BAT (bromoacetamidobenzyl-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid) and labeled with the radioactive isotope copper-64 (Cu-64), this agent delivers targeted radiation to tumor sites expressing the antigen recognized by MAb 1A3. Preclinical studies in hamsters bearing GW39 human colorectal carcinoma xenografts have demonstrated both tumor localization and therapeutic efficacy of this agent at specific dose ranges[1][3][7]. The mechanism involves selective binding to tumor-associated antigens followed by localized delivery of beta radiation from Cu-64 decay.
- Other names
- copper-64-labeled monoclonal antibody 1A3copper64-labeled monoclonal antibody 1A3copper 64-labeled monoclonal antibody 1A3Cu-64-MAb 1A3Cu64-MAb 1A3Cu 64-MAb 1A3
02
Targets
NeuGcGM3 (N-glycolyl-GM3 ganglioside)
Beyond the preview
Go deeper on copper-64-labeled MAB 1A3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on copper-64-labeled MAB 1A3.